[go: up one dir, main page]

WO2000073493A3 - A nematode drug screen for modulators of mammalian disorders - Google Patents

A nematode drug screen for modulators of mammalian disorders Download PDF

Info

Publication number
WO2000073493A3
WO2000073493A3 PCT/US2000/014678 US0014678W WO0073493A3 WO 2000073493 A3 WO2000073493 A3 WO 2000073493A3 US 0014678 W US0014678 W US 0014678W WO 0073493 A3 WO0073493 A3 WO 0073493A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulators
methods
disease
mammalian
modulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/014678
Other languages
French (fr)
Other versions
WO2000073493A2 (en
Inventor
Mark E Gurney
Timothy G Geary
Brenda R Ellerbrock
Eileen M Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Priority to AU52992/00A priority Critical patent/AU5299200A/en
Priority to EP00937874A priority patent/EP1180165A2/en
Publication of WO2000073493A2 publication Critical patent/WO2000073493A2/en
Publication of WO2000073493A3 publication Critical patent/WO2000073493A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
    • G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
    • G01N2333/43534—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G01N2400/24—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar beta-D-Glucans, i.e. having beta 1,n (n=3,4,6) linkages between saccharide units, e.g. xanthan
    • G01N2400/28—Chitin, chitosan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides rapid, versatile, and economic assay methods to screen for modulators of egg laying behavior in nematodes, by determining the activity of chitinase in the culture medium, thereby screening for candidate compounds that modulate a trait characteristic of mammalian disorders or diseases such as Alzheimer's disease, Ras-inducible cancer, and cardiopulmonary disease characterized by aberrant potassium channel function, among others. Also provided are modulators identified using the methods of the invention, pharmaceutical compositions including the modulators, and methods of using the modulators or pharmaceutical compositions to modulate a mammalian disorder or disease.
PCT/US2000/014678 1999-05-27 2000-05-26 A nematode drug screen for modulators of mammalian disorders Ceased WO2000073493A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU52992/00A AU5299200A (en) 1999-05-27 2000-05-26 A nematode drug screen for modulators of mammalian disorders
EP00937874A EP1180165A2 (en) 1999-05-27 2000-05-26 A nematode drug screen for modulators of mammalian disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13617399P 1999-05-27 1999-05-27
US60/136,173 1999-05-27

Publications (2)

Publication Number Publication Date
WO2000073493A2 WO2000073493A2 (en) 2000-12-07
WO2000073493A3 true WO2000073493A3 (en) 2001-05-31

Family

ID=22471665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014678 Ceased WO2000073493A2 (en) 1999-05-27 2000-05-26 A nematode drug screen for modulators of mammalian disorders

Country Status (3)

Country Link
EP (1) EP1180165A2 (en)
AU (1) AU5299200A (en)
WO (1) WO2000073493A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2359626B (en) * 1999-04-15 2002-05-01 Devgen Nv Compound screening method
ATE335002T1 (en) * 2002-05-15 2006-08-15 Devgen Nv METHODS FOR THE IDENTIFICATION AND DEVELOPMENT OF COMPONENTS THAT INTERACT WITH POTENTIALLY DEPENDENT POTASSIUM CHANNELS OF THE KV4 FAMILY
WO2004061096A1 (en) * 2003-01-07 2004-07-22 Genova, Ltd. Secreted polypeptide species (fragments from chitotriosidase) reduced in cardiovascular disorders
EP1834180A2 (en) * 2004-12-15 2007-09-19 Schering Corporation Functional assays for cholesterol absorption inhibitors
CN105738585A (en) * 2014-12-09 2016-07-06 兰州红虫生物工程有限责任公司 Drug screening kit
CN105738329B (en) * 2014-12-09 2019-05-07 费好义 Screening anti-tumor medicine kit and its application method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032623A1 (en) * 1997-12-19 1999-07-01 Pharmacia & Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
WO1999032619A1 (en) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Genetic inhibition by double-stranded rna
WO2000063427A2 (en) * 1999-04-15 2000-10-26 Devgen Nv Compound screening method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032623A1 (en) * 1997-12-19 1999-07-01 Pharmacia & Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
WO1999032619A1 (en) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Genetic inhibition by double-stranded rna
WO2000063427A2 (en) * 1999-04-15 2000-10-26 Devgen Nv Compound screening method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEARY T G (REPRINT) ET AL: "Mechanism-based screening: discovery of the next generation of anthelmintics depends upon more basic research", INTERNATIONAL JOURNAL FOR PARASITOLOGY, (JAN 1999) VOL. 29, NO. 1, PP. 105-112. PUBLISHER: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND. ISSN: 0020-7519., PHARMACIA & UPJOHN INC, ANIM HLTH DISCOVERY RES, 301 HENRIETTA ST, KALAMAZOO, MI 49007 (Reprint), XP000972176 *
GEARY T G (REPRINT): "APPROACHING HELMINTH BIOLOGY FROM THE MOLECULAR DIRECTION", PARASITOLOGY TODAY, (OCT 1996) VOL. 12, NO. 10, PP. 373-375. ISSN: 0169-4758., PHARMACIA & UPJOHN INC, ANIM HLTH DISCOVERY RES, 301 HENRIETTA ST, KALAMAZOO, MI, 49007 (Reprint), XP000972039 *

Also Published As

Publication number Publication date
WO2000073493A2 (en) 2000-12-07
EP1180165A2 (en) 2002-02-20
AU5299200A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
WO2001071009A3 (en) Whole-body optical imaging of gene expression and uses thereof
PT729468E (en) NON-PEPTIDIC ANTAGONISTS OF TAQUIKININES RECEPTORS
WO2002099051A3 (en) Nits as modifiers of the p53 pathway and methods of use
CA2220461A1 (en) Therapeutic compounds comprised of anti-fc receptor antibodies
DK1054887T3 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists
TR200000812T2 (en) 2-methyl-thieno-benzodiazepine formulation.
DE69733572D1 (en) MATERIAL HEMOCHROMATOSIS GENE
EP0686629A3 (en) Cyclohexyl tachykinine receptor antagonists
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
NO931889L (en) Protease and related DNA compounds
PT938308E (en) ANTIPARASITORY AGENTS
WO2000073493A3 (en) A nematode drug screen for modulators of mammalian disorders
ATE356200T1 (en) KCNQ POTASSIUM CHANNELS AND METHOD FOR MODULATING THEM
WO2005000875A3 (en) Compositions and methods comprising a ligand of chemerin receptor
ES2123582T3 (en) PROTEIN WITH BONE FORMATION CAPACITY AND PROCEDURE FOR ITS PRODUCTION.
ID16007A (en) METHODS FOR SEPARATION OF 2-HYDROXIC ACID-4-METHYL IOP BUTIRAT OR MHA
DK1007666T3 (en) Neurturin
PT1267915E (en) METHODS FOR TREATING DISEASES WITH PROTEIN C ACTIVATED
DK1196442T3 (en) VGF polypeptides and methods for the treatment of VGF-related disorders
ATE420176T1 (en) THE EAAT2 PROMOTER AND USE THEREOF
EP1255110A3 (en) Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
BR9709245A (en) Use of a genetic modification in the gene for human protein beta3 subunit for the diagnosis of diseases
WO2001066709A3 (en) Sphingomyelinase enzymes and uses relating thereto
PT1196188E (en) SELECTIVE MONOCLONAL ANTIBODIES FOR THE FCV AND ITS USE FOR THE TREATMENT OF FCV-RELATED DISEASES
ITMI951629A0 (en) MANNEQUIN FOR THE SIMULATION OF HEART DISEASE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000937874

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000937874

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000937874

Country of ref document: EP